Drugs of Abuse 7A Panel, Urine - Screen Only

0090449
copy
 

Copy Utility


emailprint
Example Reports
Negative
Positive

Ordering Recommendation

Useful for general screening in contexts of compliance and/or abuse. For follow-up testing of a presumptive result, confirmatory testing by mass spectrometry is recommended. For automatic reflex testing on all presumptive positives, Drug Panel 7A, Urine - Screen with Reflex to Confirmation/Quantitation (0092185) is recommended.

This test does not distinguish between the delta-8 and delta-9 forms of THC or their metabolites.

Mnemonic

CDTI7A

Methodology

Qualitative Enzyme Multiplied Immunoassay Technique/Enzymatic Assay

Performed

Sun-Sat

Reported

1-2 days

New York DOH Approval Status

This test is New York DOH approved.

Specimen Required

Patient Preparation
Collect

Random urine.

Specimen Preparation

Transfer 4 mL urine with no additives or preservatives to an ARUP Standard Transport Tube. (Min: 2 mL)

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions

Specimens exposed to repeated freeze/thaw cycles.

Remarks
Stability

Ambient: 1 week; Refrigerated: 1 month; Frozen: 1 month

Reference Interval

Effective August 17, 2015

Drugs Covered and Cutoff Concentrations
Drugs
Screen
THC (Cannabinoids) 20 ng/mL
Cocaine 150 ng/mL
Opiates 300 ng/mL
Oxycodone 100 ng/mL
Phencyclidine 25 ng/mL
Amphetamines 300 ng/mL
MDMA (Ecstasy) 500 ng/mL
Barbiturates 200 ng/mL
Benzodiazepines 200 ng/mL
Alcohol 40 mg/dL

Interpretive Data

This is a screening test only. False positive and false negative results can occur. Positive results are not automatically reflexed to a confirmatory test. Confirmation by GC/MS and/or LC-MS/MS must be requested separately. Confirmatory testing for drugs and/or drug classes detected by this screening test is recommended.

The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration at which the screening test can detect a drug or metabolite varies within a drug class. The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

For medical purposes only; not valid for forensic use.

Compliance Category

FDA

Note

Hotline History

View Hotline History

 

Hotline History

Date of Change
Test Name Change
Methodology
Performance/Reported Schedule
Specimen Requirements
Reference Interval
Interpretive Data
Note
CPT Code
Component Change
Other Interface Change
New Test
Inactive
05/17/2021
X
N/A

CPT Codes

80307

Are you an ARUP Client? Click here for your pricing.

Components

Component Test Code* Component Chart Name LOINC
0090381 Amphetamines, Urn, Screen 3349-8
0090382 Barbiturates, Urn, Screen 3377-9
0090383 Benzodiazepines, Urn, Screen 3390-2
0090386 Creatinine, Urine 2161-8
0090388 Cocaine, Urn, Screen 3397-7
0090396 Opiates, Urn, Screen 3879-4
0090397 Phencyclidine, Urn, Screen 19659-2
0090398 THC, Urn, Screen 18282-4
0090417 Drug Panel 7A, Screen Only - Comments 77202-0
0090488 Alcohol, Urn, Screen 5644-0
2004776 Oxycodone, Urn, Screen 19644-4
2004778 MDMA, Urn, Screen 19571-9
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • 7-Amino Flunitrazepam, Flunitrazepam metabolite
  • Alcohol
  • Alprazolam
  • Amobarbital
  • Amphetamines
  • Amytal
  • Ativan
  • Barbita
  • Barbiturates
  • Benzodiazepines
  • Lorazepam
  • Pain Management
  • Phencyclidine
  • Phenobarbital
  • Rohypnol
  • Xanax
Drugs of Abuse 7A Panel, Urine - Screen Only